VRCA - Verrica Pharmaceuticals Inc
IEX Last Trade
2.37
-0.070 -2.954%
Share volume: 1,023,120
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.44
-0.07
-2.87%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-07 | 2023-03-06 | 2023-05-09 | 2023-08-08 | 2023-11-09 | 2024-02-29 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 63.436 M | 49.147 M | 44.721 M | 68.639 M | 62.201 M | 97.148 M | 81.597 M | 66.307 M | |
| Current Assets | 57.341 M | 43.395 M | 39.115 M | 63.097 M | 56.777 M | 91.725 M | 77.530 M | 61.376 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 279.000 K | 1.022 M | 2.499 M | |
| Other Current Assets | 2.725 M | 3.522 M | 4.355 M | 3.089 M | 1.464 M | 3.066 M | 2.545 M | 2.344 M | |
| Short Term Investments | 2.725 M | 3.522 M | 4.355 M | 3.089 M | 1.464 M | 3.066 M | 2.545 M | 2.344 M | |
| Total Receivables | 218.000 K | 419.000 K | 487.000 K | 56.000 K | 173.000 K | 4.072 M | 4.416 M | 7.594 M | |
| Current Cash | 14.398 M | 39.454 M | 34.273 M | 59.952 M | 55.140 M | 84.308 M | 69.547 M | 48.939 M | |
| Total Non-current Assets | 6.095 M | 5.752 M | 5.606 M | 5.542 M | 5.424 M | 5.423 M | 4.067 M | 4.931 M | |
| Property Plant Equipment | 4.044 M | 4.018 M | 3.887 M | 3.801 M | 3.688 M | 3.558 M | 1.052 M | 937.000 K | |
| Other Assets | 2.051 M | 1.734 M | 1.719 M | 1.741 M | 1.736 M | 1.865 M | 3.015 M | 3.994 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 63.436 M | 49.147 M | 44.721 M | 68.639 M | 62.201 M | 97.148 M | 81.597 M | 66.307 M | |
| Total liabilities | 47.103 M | 4.382 M | 4.688 M | 3.793 M | 6.801 M | 54.845 M | 61.834 M | 64.799 M | |
| Total current liabilities | 45.711 M | 3.078 M | 3.459 M | 2.643 M | 5.731 M | 11.374 M | 17.024 M | 19.365 M | |
| Accounts Payable | 714.000 K | 137.000 K | 507.000 K | 575.000 K | 2.057 M | 1.925 M | 2.464 M | 2.527 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 42.583 M | 291.000 K | 297.000 K | 302.000 K | 309.000 K | 347.000 K | 700.000 K | 1.010 M | |
| Long term debt | 1.392 M | 1.304 M | 1.229 M | 1.150 M | 1.070 M | 43.471 M | 44.810 M | 45.434 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 16.333 M | 44.765 M | 40.033 M | 64.846 M | 55.400 M | 42.303 M | 19.763 M | 1.508 M | |
| Common stock | 27.519 M | 40.305 M | 41.311 M | 43.023 M | 45.917 M | 46.074 M | 46.356 M | 46.484 M | |
| Retained earnings | -157.604 M | -157.521 M | -163.453 M | -170.042 M | -181.032 M | -205.834 M | -230.448 M | -250.779 M |